Hybrid formation between the intracellular faces of the bradykinin B2 and angiotensin II AT1 receptors and signal transduction

International Immunopharmacology

Volumn 2, Issue 13-14, 2002, Pages 1807-1822

  Yu, Jun ^a   Prado, Gregory N ^a   Taylor, Linda ^a   Pal Ghosh, Ruma ^a   Polgar, Peter ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin AT1 receptor; Bradykinin B2 receptor; Cell signaling; Connective tissue growth factor; CTGF; Endocytosis; GPCR; Internalization; Microdomains; PGE2 receptor EP2; Transactivation; Translocation; Tyrosine kinases; Tyrosine phosphatases

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; BETA ARRESTIN; BRADYKININ; BRADYKININ B2 RECEPTOR; CELL PROTEIN; CLATHRIN; CONNECTIVE TISSUE GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHATASE; PROTEIN CDC42; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RNA; ANGIOTENSIN RECEPTOR; BRADYKININ RECEPTOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SPECIFICITY; CELL TYPE; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HYBRIDIZATION; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; RECEPTOR BINDING; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; PHYSIOLOGY; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, BRADYKININ B2; RECEPTORS, ANGIOTENSIN; RECEPTORS, BRADYKININ; SIGNAL TRANSDUCTION;

EID: 0036891510     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00177-7     Document Type: Article

References (125)

1. Ardaillou R. Angiotensin II receptors. J. Am. Soc. Nephrol. 10:1999;S30-S39.
2. Regoli D. Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system. J. Cardiovasc. Pharmacol. 6:1984;S401-S412. [Suppl.].
3. Han E.D., MacFarlane R.C., Mulligan A.N., Scafidi J., Davis A.E. III Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. 109:2002;1057-1063.
4. Kaplan A.P., Joseph K., Silverberg M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 109:2002;195-209.
5. Prado G.N., Mierke D.F., LeBlanc T., Manseau M., Taylor L.et al. Role of hydroxyl containing residues in the intracellular region of rat bradykinin B(2) receptor in signal transduction, receptor internalization, and resensitization. J. Cell. Biochem. 83:2001;435-447.
6. Ricupero D., Taylor L., Tiucko A., Navarro J., Polgar P. Mechanisms in bradykinin stimulated arachidonate release and synthesis of prostaglandin and platelet activating factor. Mediat. Inflamm. 1:1992;133-140.
7. Ricupero D.A., Polgar P., Taylor L., Sowell M.O., Gao Y.et al. Enhanced bradykinin-stimulated phospholipase C activity in murine embryonic stem cells lacking the G-protein alphaq-subunit. J. Biochem. 327(Pt. 3):1997;803-809.
8. Wong S.K., Parker E.M., Ross E.M. Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists. J. Biol. Chem. 265:1990;6219-6224.
9. England B.P., Ackerman M.S., Barrett R.W. A chimeric D2 dopamine/m1 muscarinic receptor with D2 binding specificity mobilizes intracellular calcium in response to dopamine. FEBS Lett. 279:1991;87-90.
10. Fathy D.B., Mathis S.A., Leeb T., Leeb-Lundberg L.M. A single position in the third transmembrane domains of the human B1 and B2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands. J. Biol. Chem. 273:1998;12208-12210.
11. Filteau F., Veilleux F., Levesque D. Effects of reciprocal chimeras between the C-terminal portion of third intracellular loops of the human dopamine D2 and D3 receptors. FEBS Lett. 447:1999;251-256.
12. Nikolaidis L.A., Doverspike A., Huerbin R., Hentosz T., Shannon R.P. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation. 105:2002;2785-2790.
13. Campbell D.J. Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE. Clin. Exp. Pharmacol. Physiol. 22:1995;903-911.
14. Berk B.C. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J. Am. Soc. Nephrol. 10:1999;S62-S68.
15. Hughes A.D. Molecular and cellular mechanisms of action of angiotensin II (AT1) receptors in vascular smooth muscle. J. Hum. Hypertens. 12:1998;275-281.
16. Wassmann S., Hilgers S., Laufs U., Bohm M., Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 22:2002;1208-1212.
17. Boffa J.J., Tharaux P.L., Placier S., Ardaillou R., Dussaule J.C., Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation. 100:1999;1901-1908.
18. Lijnen P.J., Petrov V.V., Fagard R.H. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J. Renin Angiotensin Aldosterone Syst. 2:2001;117-122.
19. Tamarat R., Silvestre J.S., Durie M., Levy B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab. Invest. 82:2002;747-756.
20. Berry C., Hamilton C.A., Brosnan M.J., Magill F.G., Berg G.et al. An investigation into the sources of superoxide production in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 101:2000;2206-2212.
21. Vaughan D.E., Lazos S.A., Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J. Clin. Invest. 95:1995;995-1001.
22. Takeda-Matsubara Y., Nakagami H., Iwai M., Cui T.X., Shiuchi T., Akishita M.et al. Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension. 39:2002;41-45.
23. Shibasaki Y., Matsubara H., Nozawa Y., Mori Y., Masaki H., Kosaki A.et al. Angiotensin II type 2 receptor inhibits epidermal growth factor receptor transactivation by increasing association of shp-1 tyrosine phosphatase. Hypertension. 38:2001;367-372.
24. Emanueli C., Maestri R., Corradi D., Marchione R., Minasi A.et al. Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation. 100:1999;2359-2365.
25. Madeddu P., Emanueli C., Maestri R., Salis M.B., Minasi A.et al. Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B(2) receptor knockout mice. Hypertension. 35:2000;391-396.
26. Yang X.P., Liu Y.H., Mehta D., Cavasin M.A., Shesely E.et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ. Res. 88:2001;1072-1079.
27. Berthiaume N., Hess F., Chen A., Regoli D., D'Orleans-Juste P. Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. Eur. J. Pharmacol. 333:1997;55-61.
28. Tsuchida S., Miyazaki Y., Matsusaka T., Hunley T.E., Inagami T.et al. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature. Kidney Int. 56:1999;509-516.
29. Iwai N, Inagami T, Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 1992;24;298(2-3):257-60.
30. Regoli D., Gobeil F., Nguyen Q.T., Jukic D., Seoane P.R.et al. Bradykinin receptor types and B2 subtypes. Life Sci. 55:1994;735-749.
31. Horn F., Weare J., Beukers M.W., Hörsch S., Bairoch A.et al. GPCRDB: an information system for G-protein-coupled receptors. Nucleic Acids Res. 26:1998;277-281.
32. Furuta H., Guo D.F., Inagami T. Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem. Biophys. Res. Commun. 183:1992;8-13.
33. Hess J.F.R., Borkowski J.A., Young G.S., Strader C.D., Ransom R.W. Cloning and pharmacological characterization of a human bradykinin BK-2 receptor. Biochem. Biophys. Res. Commun. 184:1992;260-268.
34. Murphy T.J., Alexander R.W., Griendling K.K., Runge M.S., Bernstein K.E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 351:1991;233-236.
35. Hunyady L., Catt K.J., Clark A.J., Gaborik Z. Mechanisms and functions of AT(1) angiotensin receptor internalization. Regul. Pept. 91:2000;29-44.
36. Kyle D.J., Chakravarty S., Sinsko J.A., Stormann T.M. A proposed model of bradykinin bound to the rat B2 receptor and its utility for drug design. J. Med. Chem. 37:1994;1347-1354.
37. Guo D.F., Furuta H., Mizukoshi M., Inagami T. The genomic organization of human angiotensin II type 1 receptor. Biochem. Biophys. Res. Commun. 200:1994;313-319.
38. Ma J.X., Wang D.Z., Ward D.C., Chen L., Dessai T., Chao J.et al. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics. 23:1994;362-369.
39. Mukae S., Aoki S., Itoh S., Nishio K., Iwata T., Ueda H.et al. Promoter polymorphism of the beta2 bradykinin receptor gene is associated with essential hypertension. Jpn. Circ. J. 63:1999;759-762.
40. Wang B., Dang A., Liu G. Genetic variation in the promoter region of the beta2 bradykinin receptor gene is associated with essential hypertension in a Chinese Han population. Hypertens. Res. 24:2001;299-302.
41. Gainer J.V., Brown N.J., Bachvarova M., Bastien L., Maltais I., Marceau F.et al. Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am. J. Hypertens. 13:2000;1268-1273.
42. Takahashi N., Murakami H., Kodama K., Kasagi F., Yamada M.et al. Association of a polymorphism at the 5′-region of the angiotensin II type 1 receptor with hypertension. Ann. Hum. Genet. 64(Pt. 3):2000;197-205.
43. Duncan J.A., Scholey J.W., Miller J.A. Angiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes. Curr. Opin. Nephrol. Hypertens. 10:2001;111-116.
44. Dzida G., Sobstyl J., Puzniak A., Golon P., Mosiewicz J., Hanzlik J. Polymorphisms of angiotensin-converting enzyme and angiotensin II receptor type 1 genes in essential hypertension in a Polish population. Med. Sci. Monit. 7:2001;1236-1241.
45. Guo D.F., Sun Y.L., Hamet P., Inagami T. The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res. 11:2001;165-180.
46. Touyz R.M., Berry C. Recent advances in angiotensin II signaling. Braz. J. Med. Biol. Res. 35:2002;1001-1015.
47. Berry C., Touyz R., Dominiczak A.F., Webb R.C., Johns D.G. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H2337-H23665.
48. Dinh D.T., Frauman A.G., Johnston C.I., Fabiani M.E. Angiotensin receptors: distribution, signalling, and function. Clin. Sci. (London). 100:2001;481-492.
49. Smith R.D., Hunyady L., Olivares-Reyes J.A., Mihalik B., Jayadev S., Catt K.J. Agonist-induced phosphorylation of the angiotensin AT1a receptor is localized to a serine/threonine-rich region of its cytoplasmic tail. Mol. Pharmacol. 54:1998;935-941.
50. Tang H., Guo D.F., Porter J.P., Wanaka Y., Inagami T. Role of cytoplasmic tail of the type 1A angiotensin II receptor in agonist- and phorbol ester-induced desensitization. Circ. Res. 82:1998;523-531.
51. Blaukat A., Alla S.A., Lohse M.J., Muller-Esterl W. Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J. Biol. Chem. 271:1996;32366-32374.
52. Prado G.N., Mierke D.F., Pellegrini M., Taylor L., Polgar P. Motif mutation of bradykinin B2 receptor second intracellular loop and proximal C terminus is critical for signal transduction, internalization, and resensitization. J. Biol. Chem. 273:1998;33548-33555.
53. Prado G.N., Mierke D.F., LeBlanc T., Manseau M., Taylor L.et al. Role of hydroxyl containing residues in the intracellular region of rat bradykinin B(2) receptor in signal transduction, receptor internalization, and resensitization. J. Cell. Biochem. 83:2001;435-447.
54. Prado G.N., Taylor L., Polgar P. Effects of intracellular tyrosine residue mutation and carboxyl terminus truncation on signal transduction and internalization of the rat bradykinin B2 receptor. J. Biol. Chem. 272:1997;14638-14642.
55. Farmer S.G., Burch R.M. Biochemical and molecular pharmacology of kinin receptors. Annu. Rev. Pharmacol. Toxicol. 32:1992;511-536.
56. Greaves M.W., Camp R.D. Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin. Arch. Dermatol. Res. 280:1988;S33-S41. [Suppl.].
57. Lee S.D., Lee B.D., Kim Y., Suh P.G., Ryu S.H. Bradykinin activates phospholipase D2 via protein kinase cdelta in PC12 cells. Neurosci. Lett. 294:2000;130-132.
58. Ushio-Fukai M., Alexander R.W., Akers M., Lyons P.R., Lassegue B., Griendling K.K. Angiotensin II receptor coupling to phospholipase D is mediated by the βγ-subunits of heterotrimeric G proteins in vascular smooth muscle cells. Mol. Pharmacol. 55:1999;142-149.
59. Choi W.S., Chahdi A., Kim Y.M., Fraundorfer P.F., Beaven M.A. Regulation of phospholipase D and secretion in mast cells by protein kinase A and other protein kinases. Ann. N. Y. Acad. 968:2002;198-212.
60. Adamson R.H., Curry F.E., Adamson G., Liu B., Jiang Y., Aktories K.et al. Rho and rho kinase modulation of barrier properties: cultures endothelial cells and intact microvessels of rats and mice. J. Physiol. 539:2002;295-308.
61. Wilk-Blaszczak M.A., Singer W.D., Quill T., Miller B., Frost J.A., Sternweis P.C.et al. The monomeric G-proteins Rac1 and/or Cdc42 are required for the inhibition of voltage-dependent calcium current by bradykinin. J. Neurosci. 17:1997;4094-4100.
62. Yamakawa T., Tanaka S., Numaguchi K., Yamakawa Y., Motley E.D., Ichihara S.et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 35:2000;313-318.
63. Laufs U., Liao J.K. Targeting Rho in cardiovascular disease. Circ. Res. 87:2000;526-528.
64. Saito Y., Berk B.C. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J. Mol. Cell. Cardiol. 33:2001;3-7.
65. Eguchi S., Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul. Pept. 91:2000;13-20.
66. Zwick E., Daub H., Aoki N., Yamaguchi-Aoki Y., Tinhofer I.et al. Critical role of calcium-dependent epidermal growth factor receptor transactivation in PC12 cell. J. Biol. Chem. 272:1997;24767-24770.
67. Gutkind J.S. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J. Biol. Chem. 273:1998;1839-1842.
68. Blaukat A., Ivankovic-Dikic I., Gronroos E., Dolfi F., Tokiwa G.et al. Adaptor proteins Grb2 and Crk couple Pyk2 with activation of specific mitogen-activated protein kinase cascades. J. Biol. Chem. 274:1999;14893-14901.
69. Murasawa S., Matsubara H., Mori Y., Masaki H., Tsutsumi Y.et al. Angiotensin II initiates tyrosine kinase Pyk2-dependent signalings leading to activation of Rac1-mediated c-Jun NH2-terminal kinase. J. Biol. Chem. 275:2000;26856-26863.
70. Graness A., Adomeit A., Heinze R., Wetzker R., Liebmann C. A novel mitogenic signaling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of a Gq/11 protein, phosphatidylinositol 3-kinase beta, and protein kinase Cepsilon. J. Biol. Chem. 273:1998;32016-32022.
71. Takahashi T., Taniguchi T., Konishi H., Kikkawa U., Ishikawa Y., Yokoyama M. Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am. J. Physiol. 276(6 Pt. 2):1999;H1927-H1934.
72. Sharif N.A., Wiernas T.K., Howe W.E., Griffin B.W., Offord E.A., Pfeifer A.M. Human corneal epithelial cell functional responses to inflammatory agents and their antagonists. Invest Ophthalmol. Vis. Sci. 39:1998;2562-2571.
73. Saito S., Frank G.D., Motley E.D., Dempsey P.J., Utsunomiya H., Inagami T.et al. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem. Biophys. Res. Commun. 294:2002;1023-1029.
74. Thuringer D., Maulon L., Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J. Biol. Chem. 277:2002;2028-2032.
75. Yu J., Prado G.N., Schreiber B., Polgar P., Taylor L. Role of prostaglandin E(2) EP receptors and cAMP in the expression of connective tissue growth factor. Arch. Biochem. Biophys. 404:2002;302-308.
76. Stork P.J., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell profileration. Trends Cell Biol. 12:2002;258-266.
77. Michel J.J., Scott J.D. AKAP mediated signal transduction. Annu. Rev. Pharmacol. Toxicol. 42:2002;235-257.
78. Feliciello A., Gottesman M.E., Avvedimento E.V. The biological functions of A-kinase anchor proteins. J. Mol. Biol. 308:2001;99-114.
79. Oakley R.H., Laporte S.A., Holt J.A., Barak L.S., Caron M.G. Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis. J. Biol. Chem. 276:2001;19452-19460.
80. Thomas W.G., Thekkumkara T.J., Baker K.M. Molecular mechanisms of angiotensin II (AT1A) receptor endocytosis. Clin. Exp. Pharmacol. Physiol. 3(Suppl):1996;S74-S80.
81. McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E.et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science. 290:2000;1574-1577.
82. Lamb M.E., De Weerd W.F., Leeb-Lundberg L.M. Agonist-promoted trafficking of human bradykinin receptors: arrestin- and dynamin-independent sequestration of the B2 receptor and bradykinin in HEK293 cells. Biochem. J. 355:2001;741-750.
83. Sabourin T., Bastien L., Bachvarov D.R., Marceau F. Agonist-induced translocation of the kinin B(1) receptor to caveolae-related rafts. Mol. Pharmacol. 61:2002;546-553.
84. Zhou X., Prado G.N., Taylor L., Yang X., Polgar P. Regulation of inducible bradykinin B1 receptor gene expression through absence of internalization and resensitization. J. Cell. Biochem. 78:2000;351-362.
85. Marletta M. Another activation switch for the endothelial nitric oxide synthase: why does it have to be so complicated? TRENDS in Biochem. Sci. 26:2001;519-521.
86. Ostrom R.S. New determinants of receptor-effector coupling: trafficking and compartmentation in membrane microdomains. Mol. Pharmacol. 61:2002;473-476.
87. Aohi H., Izumo S., Sadoshima J. Angiotensin II activates RhoA incardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ. Res. 82:1998;666-676.
88. 1 receptor. J. Biol. Chem. 272:1997;23382-23388.
89. Venema R.C., Ju H., Venema V.J., Schieffer B., Harp J.B., Ling B.N.et al. Angiotensin II-induced association of phospholipase Cgamma1 with the G-protein-coupled AT1 receptor. J. Biol. Chem. 273:1998;7703-7708.
90. Venema V.J., Ju H., Sun J., Eaton D.C., Marrero M.B., Venema R.C. Bradykinin stimulates the tyrosine phosphorylation and bradykinin B2 receptor association of phospholipase C gamma 1 in vascular endothelial cells. Biochem. Biophys. Res. Commun. 246:1998;70-75.
91. Alric C., Pecher C., Cellier E., Schanstra J.P., Poirier B., Chevalier J.et al. Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int. 62:2002;412-421.
92. Graness A., Hanke S., Boehmer F.D., Presek P., Liebmann C. Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells. Biochem. J. 347:2000;441-447.
93. 9/11-mediated phospholipase Cβ activity. Mol. Pharmacol. 62:2002;281-288.
94. Wang C., Jayadev S., Escobedo J.A. Identification of a domain in the angiotensin II type 1 receptor determining Gq coupling by the use of receptor chimeras. J. Biol. Chem. 270:1995;16677-16682.
95. Davie L., Lehtonen J.Y., Hayashida W., Dzau V.J., Horiuch M. Intracellular third loops in AT1 and AT2 receptors determine subtype specificity. Life Sci. 69:2001;509-516.
96. Conchon S., Barrault M.B., Miserey S., Corvol P., Clauser E. The C-terminal third intracellular loop of the rat AT1A angiotensin receptor plays a key role in G protein coupling specificity and transduction of the mitogenic signal. J. Biol. Chem. 272:1997;25566-25572.
97. Faussner A., Proud D., Towns M., Bathon J.M. Influence of the cytosolic carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction. J. Biol. Chem. 273:1998;2617-2623.
98. Arora K.K., Krsmanovic L.Z., Mores N., O'Farrell H., Catt K.J. Mediation of cyclic AMP signaling by the first intracellular loop of the gonadotropin-releasing hormone receptor. J. Biol. Chem. 273:1998;25581-25586.
99. Wu S.V., Yang M., Avedian D., Birnbaumer M., Walsh J.H. Single amino acid substitution of serine82 to asparagine in first intracellular loop of human cholecystokinin (CCK)-B receptor confers full cyclic AMP responses to CCK and gastrin. Mol. Pharmacol. 55:1999;780-795.
100. Quitterer U., Zaki E., AbdAlla S. Investigation of the extracellular accessibility of the connecting loop between membrane domains I and II of the bradykinin B2 receptor. J. Biol. Chem. 274:1999;14773-14778.
101. Yu J., Prado G.N., Taylor L., Piserchio A., Gupta A., Mierke D.F.et al. Global chimeric exchanges within the intracellular face of the bradykinin B2 receptor with corresponding angiotensin II type 1a receptor regions: generation of fully functional hybrids showing characteristic signaling of the AT1a receptor. J. Cell. Biochem. 85:2002;809-819.
102. Piserchio A., Prado G.N., Zhang R., Taylor L., Yu J., Polgar P.et al. Structural insight into the role of the second intracellular face of the bradykinin B2 receptor in signaling and internalization. Biopolymers. 63:2002;239-246.
103. Balmforth A.J., Lee A.J., Bajaj B.P., Dickinson C.J., Warburton P., Ball S.G. Functional domains of the C-terminus of the rat angiotensin AT1A receptor. Eur. J. Pharmacol. 291:1995;135-141.
104. Qian H., Pipolo L., Thomas W.G. Association of beta-Arrestin 1 with the type 1A angiotensin II receptor involves phosphorylation of the receptor carbosyl terminus and correlates with receptor internalization. Mol. Endocrinol. 15:2001;1706-1719.
105. Leask A., Holmes A., Abraham D.J. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr. Rheumatol. Rep. 4:2002;136-142.
106. Igarashi A., Nashiro K., Kikuchi K., Sato S., Ihn H.et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J. Invest. Dermatol. 106:1996;729-733.
107. Gupta S., Clarkson M.R., Duggan J., Brady H.R. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int. 58:2000;1389-1399.
108. Duncan M.R., Frazier K.S., Abramson S., Williams S., Klapper H., Huang X.et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J. 13:1999;1774-1786.
109. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 8:1997;171-179.
110. Shimo T., Nakanishi T., Nishida T., Asano M., Kanyama M.et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J. Biochem. 126:1999;137-145.
111. Moussad E.E., Brigstock D.R. Connective tissue growth factor: what's in a name? Mol. Genet. Metab. 71:2000;276-392.
112. Oemar B.S., Werner A., Garnier J.M., Do D.D., Godoy N.et al. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation. 95:1997;831-839.
113. Denton C.P., Abrahamm D.J. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr. Opin. Rheumatol. 13:2001;505-511.
114. Twigg S.M., Joly A.H., Chen M.M., Tsubaki J., Kim H.S.et al. Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology. 143:2002;1260-1269.
115. Surveyor G.A., Wilson A.K., Brigstock D.R. Localization of connective tissue growth factor during the period of embryo implantation in the mouse. Biol. Reprod. 59:1998;1207-1213.
116. Choung J., Taylor L., Thomas K., Zhou X., Kagan H.et al. Role of EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen alpha1, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. J. Cell. Biochem. 71:1998;254-263.
117. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 34(4 Pt. 1):2001;745-750.
118. Marshall R.P., McAnulty R.J., Laurent G.J. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am. J. Respir. Crit. Care Med. 161:2000;1999-2004.
119. Kawano H., Do Y.S., Kawano Y., Starnes V., Barr M.et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation. 101:2000;1130-1137.
120. Tharaux P.L., Chatziantoniou C., Fakhouri F., Dussaule J.C. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension. 36:2000;330-336.
121. Benetos A., Levy B.I., Lacolley P., Taillard F., Duriez M., Safar M.E. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler. Thromb. Vasc. Biol. 17:1997;3196-3201.
122. Wollert K.C., Drexler H. The kallikrein-kinin system in post-myocardial infarction cardiac remodeling. Am. J. Cardiol. 80:1997;158A-161A.
123. Douillet C.D., Velarde V., Christopher J.T., Mayfield R.K., Trojanowska M.E., Jaffa A.A. Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK. Am. J. Physiol. Heart Circ. Physiol. 279:2000;H2829-H2837.
124. Finckenberg P., Lassila M., Inkinen K., Pere A.K., Krogerus L.et al. Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation. 71:2001;951-958.
125. Candido R., Jandeleit-Dahm K.A., Cao Z., Nesteroff S.P., Burns W.C.et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation. 106:2002;246-253.